台灣臨床試驗主持人資料庫|TPIDB

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

Condition/Disease

Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations
Test Drug

ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

Condition/Disease

NSCLC
Test Drug

Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴

Taipei Veterans General Hospital

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2015-07-01 - 2023-10-27

Phase III

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Condition/Disease

Renal Cell Carcinoma
Test Drug

Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

黃逸修

Taipei Veterans General Hospital

Division of Hematology & Oncology

張文震

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-10-01 - 2021-08-31

Phase II

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Condition/Disease

Advanced Pancreatic Cancer
Test Drug

Cabiralizumab (BMS-986227, FPA008)

Participate Sites
2Sites

Terminated2Sites

李重賓

Taipei Veterans General Hospital

Digestive System Department

2019-05-24 - 2021-12-31

Phase I

Condition/Disease
Test Drug

Participate Sites
3Sites

Recruiting3Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-04-01 - 2018-12-04

Phase I

Phase I Study of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Condition/Disease

Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Test Drug

NC-6004

Participate Sites
3Sites

Terminated3Sites

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

-

IIT

Phase II

Condition/Disease
Test Drug

Participate Sites
1Sites

周元華

Taipei Veterans General Hospital

未分科

Search Result

List